Runda Medical's 39.6 million acquisition of RBM's 43.1% equity industry's full coverage

RBM's original domestic sole agent was released in March 2016. After the completion of this merger, Runda Medical will not only become the only domestic sales company, but also become the largest shareholder of RBM.

Runda Medical's 39.6 million acquisition of 43.1% equity of RBM Company

M&A tripartite company introduction

OrbiMed Investment Group

As one of the world's largest biomedical investment companies, OrbiMed manages approximately $15 billion in net assets. Committed to finding and supporting biomedical and life science companies that promote human health. Investment projects cover biopharmaceuticals, life sciences, medical devices, medical services and diagnostics.

RBM

RBM is a company that develops, manufactures and markets POCT, environmental diagnostics and laboratory diagnostic products. The company was founded in Vancouver in 1980.

RBM's products include cardiovascular disease (cardiac marker) diagnosis, infectious disease diagnosis, biodefense products, and environmental diagnosis. The main products are RAMP? Heart marker diagnostic products account for about 90% of RBM's total revenue.

RBM sells cardiovascular instruments and consumables mainly through distributors, with distributors in the United States, China, Russia, Japan and other countries. RBM's revenue in the past three years mainly comes from the United States, Europe and Asia, with China accounting for more than 60% of total revenue. In 2015, RBM achieved sales revenue of $11.97 million, of which $7.52 million came from China.

From Runda's public RBM earnings report, from 2013 to 2015, RBM's operating conditions have gone from bad to worse, with a cumulative loss of 120 million US dollars by the end of 2015. RBM revealed in its earnings report that due to the obvious advantages of competitors in product line and capital, coupled with the insufficient construction of RBM's own sales team and distribution channels. In this situation, the company's market share and revenue capacity have gradually declined. At present, RBM's valuation is only more than 10 million US dollars, Runda Medical chose to bargain at this time is appropriate.

Runda Medical's 39.6 million acquisition of 43.1% equity of RBM Company

Anti-Aging

China Anti-Aging Suppliers

Here you can find the related products in Anti-Aging, we are professional manufacturer of Anti-Aging. We focused on international export product development, production and sales. We have improved quality control processes of Anti-Aging to ensure each export qualified product.

If you want to know more about the products in Anti-Aging, please click the Product details to view parameters, models, pictures, prices and Other information about Anti-Aging.

Whatever you are a group or individual, we will do our best to provide you with accurate and comprehensive message about Anti-Aging!

Here you can find the related products in Anti-Aging, we are professional manufacturer of Anti-Aging. We focused on international export product development, production and sales.

Acetyl Hexapeptide-8,achirellin,polypeptide, Anti-Aging,peptide

Xi'an Gawen Biotechnology Co., Ltd , https://www.ahualyn-bio.com

Posted on